A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBC...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/full |
_version_ | 1797837907517505536 |
---|---|
author | Adrián Mosquera Orgueira Adrián Mosquera Orgueira Jose Ángel Díaz Arías Jose Ángel Díaz Arías Rocio Serrano Martín Rocio Serrano Martín Victor Portela Piñeiro Victor Portela Piñeiro Miguel Cid López Miguel Cid López Andrés Peleteiro Raíndo Andrés Peleteiro Raíndo Laura Bao Pérez Laura Bao Pérez Marta Sonia González Pérez Marta Sonia González Pérez Manuel Mateo Pérez Encinas Manuel Mateo Pérez Encinas Máximo Francisco Fraga Rodríguez Máximo Francisco Fraga Rodríguez Juan Carlos Vallejo Llamas Juan Carlos Vallejo Llamas José Luis Bello López José Luis Bello López |
author_facet | Adrián Mosquera Orgueira Adrián Mosquera Orgueira Jose Ángel Díaz Arías Jose Ángel Díaz Arías Rocio Serrano Martín Rocio Serrano Martín Victor Portela Piñeiro Victor Portela Piñeiro Miguel Cid López Miguel Cid López Andrés Peleteiro Raíndo Andrés Peleteiro Raíndo Laura Bao Pérez Laura Bao Pérez Marta Sonia González Pérez Marta Sonia González Pérez Manuel Mateo Pérez Encinas Manuel Mateo Pérez Encinas Máximo Francisco Fraga Rodríguez Máximo Francisco Fraga Rodríguez Juan Carlos Vallejo Llamas Juan Carlos Vallejo Llamas José Luis Bello López José Luis Bello López |
author_sort | Adrián Mosquera Orgueira |
collection | DOAJ |
description | Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups. |
first_indexed | 2024-04-09T15:33:16Z |
format | Article |
id | doaj.art-617f5691a8e74047b11c6b9eeaa33179 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-04-09T15:33:16Z |
publishDate | 2023-04-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-617f5691a8e74047b11c6b9eeaa331792023-04-28T05:29:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11576461157646A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphomaAdrián Mosquera Orgueira0Adrián Mosquera Orgueira1Jose Ángel Díaz Arías2Jose Ángel Díaz Arías3Rocio Serrano Martín4Rocio Serrano Martín5Victor Portela Piñeiro6Victor Portela Piñeiro7Miguel Cid López8Miguel Cid López9Andrés Peleteiro Raíndo10Andrés Peleteiro Raíndo11Laura Bao Pérez12Laura Bao Pérez13Marta Sonia González Pérez14Marta Sonia González Pérez15Manuel Mateo Pérez Encinas16Manuel Mateo Pérez Encinas17Máximo Francisco Fraga Rodríguez18Máximo Francisco Fraga Rodríguez19Juan Carlos Vallejo Llamas20Juan Carlos Vallejo Llamas21José Luis Bello López22José Luis Bello López23University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainDiffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups.https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/fullmachie learningDLBCL - diffuse large B cell lymphomabortezomibR-CHOPlymphomagenomics |
spellingShingle | Adrián Mosquera Orgueira Adrián Mosquera Orgueira Jose Ángel Díaz Arías Jose Ángel Díaz Arías Rocio Serrano Martín Rocio Serrano Martín Victor Portela Piñeiro Victor Portela Piñeiro Miguel Cid López Miguel Cid López Andrés Peleteiro Raíndo Andrés Peleteiro Raíndo Laura Bao Pérez Laura Bao Pérez Marta Sonia González Pérez Marta Sonia González Pérez Manuel Mateo Pérez Encinas Manuel Mateo Pérez Encinas Máximo Francisco Fraga Rodríguez Máximo Francisco Fraga Rodríguez Juan Carlos Vallejo Llamas Juan Carlos Vallejo Llamas José Luis Bello López José Luis Bello López A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma Frontiers in Oncology machie learning DLBCL - diffuse large B cell lymphoma bortezomib R-CHOP lymphoma genomics |
title | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_full | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_fullStr | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_full_unstemmed | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_short | A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma |
title_sort | prognostic model based on gene expression parameters predicts a better response to bortezomib containing immunochemotherapy in diffuse large b cell lymphoma |
topic | machie learning DLBCL - diffuse large B cell lymphoma bortezomib R-CHOP lymphoma genomics |
url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/full |
work_keys_str_mv | AT adrianmosqueraorgueira aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT adrianmosqueraorgueira aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseangeldiazarias aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseangeldiazarias aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT rocioserranomartin aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT rocioserranomartin aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT victorportelapineiro aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT victorportelapineiro aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT miguelcidlopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT miguelcidlopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT andrespeleteiroraindo aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT andrespeleteiroraindo aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT laurabaoperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT laurabaoperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT martasoniagonzalezperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT martasoniagonzalezperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT manuelmateoperezencinas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT manuelmateoperezencinas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT maximofranciscofragarodriguez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT maximofranciscofragarodriguez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT juancarlosvallejollamas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT juancarlosvallejollamas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseluisbellolopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseluisbellolopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT adrianmosqueraorgueira prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT adrianmosqueraorgueira prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseangeldiazarias prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseangeldiazarias prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT rocioserranomartin prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT rocioserranomartin prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT victorportelapineiro prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT victorportelapineiro prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT miguelcidlopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT miguelcidlopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT andrespeleteiroraindo prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT andrespeleteiroraindo prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT laurabaoperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT laurabaoperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT martasoniagonzalezperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT martasoniagonzalezperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT manuelmateoperezencinas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT manuelmateoperezencinas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT maximofranciscofragarodriguez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT maximofranciscofragarodriguez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT juancarlosvallejollamas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT juancarlosvallejollamas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseluisbellolopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma AT joseluisbellolopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma |